The purpose of this study is to determine whether giving abciximab (ReoPro) to children with sickle cell disease who are hospitalized for acute pain crisis will improve their pain and shorten the time spent in the hospital, when compared with standard supportive care.

Start Date01 Nov 2013

Sponsor / Collaborator

St. Louis University

NCT03087539

/ Unknown statusPhase 2

Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab® (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double Blind, Placebo-controlled and Parallel Group Trial

Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab® (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double-Blind, Placebo-controlled and Parallel Group Trial

Start Date01 May 2013

Sponsor / Collaborator

ISU Abxis Co., Ltd.

NCT02105870

/ Unknown statusNot ApplicableIIT

A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction.
The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.

Start Date01 Feb 2012

Sponsor / Collaborator

University of Melbourne

100 Clinical Results associated with Abciximab

100 Translational Medicine associated with Abciximab

100 Patents (Medical) associated with Abciximab

2,298

Literatures (Medical) associated with Abciximab

02 May 2025·MEDICINE

Coronary artery ectasia presenting as acute coronary syndrome and misinterpreted as coronary artery perforation: Case report

Article

Author: Park, Chang-Bum ; Kim, Narae ; Cho, Jin-Man ; Jeon, Hongki ; Yang, In-Ho

Rationale::

Coronary artery ectasia (CAE), characterized by diffuse dilation, can be associated with total thrombotic occlusion, leading to acute coronary syndrome. In such cases, distal vessel morphology can be highly unpredictable, potentially causing confusion during percutaneous coronary intervention (PCI).

Patient concerns::

A 47-year-old man presented with sudden chest pain. Acute coronary syndrome was suspected based on symptom and elevated troponin I levels.

Diagnoses::

Coronary angiography revealed diffuse CAE and total occlusion of mid-left circumflex artery.

Interventions::

Due to the large thrombus, aspiration thrombectomy, intracoronary abciximab, and repeated balloon angioplasty were performed. After these procedures, there was absence of flow beyond the lesion, and huge extravasation around the vessel, resembling a coronary artery perforation. Considering various factors, we concluded it was not a perforation and subsequently performed intravascular ultrasound-guided PCI on the ectatic culprit vessel. After successful PCI, he was discharged on aspirin and clopidogrel. Due to heartburn, dual antiplatelet therapy was de-escalated to clopidogrel monotherapy after 6 months.

Outcomes::

During the follow-up, he remained stable, and a 9-month coronary angiography confirmed patent stent without lesion progression.

Lessons::

Stagnant flow in dilated vessels can cause local dye deposition, which may resemble procedure-induced perforation or dissection, necessitating heightened caution during PCI. Intravascular ultrasound is valuable for accurate assessment of lesions in CAE. Thrombectomy and glycoprotein IIb/IIIa inhibitors would be considered to manage high thrombus burden. Due to its diverse clinical presentations, CAE requires an individualized strategy, and can also be treated with simple PCI followed by dual antiplatelet therapy.

01 Mar 2025·BMJ Open

Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study

Article

Author: Khan, Shaheer ; Jalil, Bisma ; Safdar, Uroosa ; Yousufzai, Elham ; Kumar, Rajesh ; Khan, Naveedullah ; Sial, Jawaid Akbar ; Tunio, Abdul Fatah ; Bhagia, Kanchan ; Naeem, Shitba ; Farooq, Fawad ; Shahid, Muhammad Owais ; Khan, Sumaira Fareed ; Mughal, Kainat Arif ; Matani, Khairaj ; Saghir, Tahir ; Hyder, Ali ; Yaqoob, Nasir ; Karim, Musa ; Ahmed, Moiz

Objectives:

Accurately predicting short-term MACE (major adverse cardiac events) following primary percutaneous coronary intervention (PCI) remains a clinical challenge. This study aims to assess the effectiveness of four established risk scores in predicting short-term MACE after primary PCI.

Design:

Prospective observational study.

Setting:

The National Institute of Cardiovascular Diseases, Karachi, Pakistan.

Participants:

We enrolled a cohort of consecutive adult patients diagnosed with ST-elevation myocardial infarction undergoing primary PCI over a 6-month period, from 1 January 2022 to 30 June 2022.

Outcome measures:

All the patients were followed at intervals of 3 months up to 12 months, and MACE events were recorded. Thrombolysis in Myocardial Infarction (TIMI), Primary Angioplasty in Myocardial Infarction (PAMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) and Global Registry of Acute Coronary Events (GRACE) scores were obtained.

Results:

A total of 2839 patients (79.3% male, mean age 55.6±11.2 years) were included. Over a median follow-up of 244 days, the composite MACE rate was 18.4% (521). All-cause mortality was 13.5% (384), reinfarction requiring revascularisation was 4.3% (121), heart failure-related rehospitalisation was 2.7% (76), stent thrombosis occurred in 5.6% (160) and cerebrovascular accident events were documented in 1% (28). The area under the curve for TIMI, PAMI, CADILLAC and GRACE scores was 0.682 (95% CI 0.655 to 0.709), 0.688 (95% CI 0.663 to 0.713), 0.686 (95% CI 0.66 to 0.711) and 0.695 (95% CI 0.669 to 0.72), respectively, for the prediction of MACE. On multivariable Cox regression, high-risk categories based on GRACE score were independent predictors of MACE with adjusted HR of 1.88 (95% CI 1.28 to 2.77; p=0.001).

Conclusions:

A significant proportion of patients experienced short-term MACE after primary PCI. While none of the assessed scores demonstrated significant predictive power, the GRACE score exhibited comparatively better predictive ability than the TIMI, PAMI and CADILLAC scores.

01 Jun 2024·Journal of thrombosis and haemostasis : JTH

A novel technique to quantify the kinetics of blood clot contraction based on the expulsion of fluorescently labeled albumin into serum

Article

Author: Litvinov, Rustem I ; Weisel, John W ; Peshkova, Alina D

BACKGROUND:

The platelet-driven contraction or retraction of blood clots has been utilized to obtain blood serum for laboratory studies, but now, in vitro clot contraction assays are used in research laboratories and clinics to assess platelet functionality. The static final extent of clot contraction measured using a clot size or expelled serum volume can be supplemented substantially with a dynamic analysis.

OBJECTIVES:

To provide a step-by-step protocol for a relatively simple and affordable new automated methodology to follow the kinetics of blood clot contraction, which allows for simultaneous measurements of various samples at a time and requires only a fluorescence plate reader.

METHODS:

The kinetics of clot contraction in whole blood was assessed by continuously detecting the fluorescence intensity of fluorescein isothiocyanate-albumin added to a blood sample before clotting and expelled into the serum during clot shrinkage.

RESULTS:

The clots are formed and fluorescence is measured in the wells of a black multiwell plate using a standard plate fluorescent reader. The specificity of this technique for clot contraction has been demonstrated by the strong inhibitory effects of blebbistatin, latrunculin A, and abciximab. To validate the new technique, increased fluorescence intensity in the contracting clots was measured in parallel with a visual decrease in clot size performed with the same blood samples.

CONCLUSION:

The resulting clot contraction dynamics based on the expulsion of fluorescein isothiocyanate-albumin can be quantified using a number of kinetic parameters as well as a phase kinetics analysis. The advantages and drawbacks of the new technique are discussed.

News (Medical) associated with Abciximab

05 Dec 2022

·www.globenewswire.com

TFF Pharmaceuticals Announces Leadership Transition

Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will step down as Chief Executive Officer and Member of the Board of Directors. Dr. Harlan F. Weisman, Vice Chairman of the Board, has been appointed Interim Chief Executive Officer, effective December 5, 2022. “On behalf of the entire Board of Directors and our shareholders, I would like to thank Glenn for his leadership and accomplishments,” said Dr. Aaron Fletcher, TFF Pharmaceuticals’ Chairman of the Board. “During Glenn’s tenure, TFF Pharmaceuticals completed its IPO financing, advanced two proprietary pipeline candidates into clinical testing, and began collaborations with many of the leading global biotechnology and pharmaceuticals companies. Under his leadership, Thin Film Freezing applications have expanded, and the platform is now recognized as a promising, next-generation technology in drug delivery. We thank Glenn for helping TFF Pharmaceuticals, and we wish him well in his future endeavors.” “I would like to thank the dedicated employees of TFF Pharmaceuticals for having the opportunity and privilege to work with all of you over the last five years on a truly unique and innovative technology that could have a great impact on many patients,” said Glenn Mattes. “I am confident that under Harlan’s leadership, this mission will continue, and I look forward to helping the Board in any way during this transition period for the Company.” “I am honored to serve as Interim Chief Executive Officer of TFF Pharmaceuticals, and I would like to thank our Board of Directors for this opportunity,” said Dr. Harlan F. Weisman. “Based upon the Company’s significant pipeline growth and impressive collaboration activity, I remain confident that we are only starting to realize the full therapeutic and commercial potential of Thin Film Freezing technology.” Harlan F. Weisman, M.D. has more than 30 years of experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. He is on advisory committees to the Johns Hopkins University Institute for Basic Biomedical Sciences and the Memorial Sloan Kettering Cancer Center Technology Development Fund. Dr. Weisman began his career in the pharmaceutical industry at Centocor, Inc., where he pioneered monoclonal antibodies as medical breakthroughs for wide therapeutic applications, including ReoPro®, REMICADE®, Simponi® and STELARA® which have combined annual sales of over $8 Billion. He was the head of R&D when Johnson & Johnson acquired Centocor in 1999. He then became President of J&J Pharmaceutical R&D, where he accelerated pipeline growth by advancing more than15 new molecular entities into late-stage development within 3 years, and gaining approvals of 10 drugs with over $15 Billion in annual sales. Dr. Weisman was promoted to Company Group Chairman, Pharmaceutical R&D, and had executive oversight of ALZA Corporation and J&J Pharmaceutical R&D, and led the acquisition and integration of 3-Dimensional Pharmaceuticals and later TransForm Pharmaceuticals. Dr. Weisman was Co-founder, Chairman and CEO of Flame Biosciences, a clinical stage company focused on the research, development, and commercialization of transformative therapies for cancer, from January 2020 to January 2022. Between December 2012 and December 2013, Dr. Weisman was Chairman and Chief Executive Officer of Coronado Biosciences, a biopharmaceutical company developing novel immunotherapies for autoimmune diseases and cancer. Dr. Weisman graduated from the University of Maryland with High Honors and the University of Maryland School of Medicine Cum Laude. After his residency in Internal Medicine at Mount Sinai Hospital in New York, he was a fellow in cardiovascular disease at Johns Hopkins Hospital, and was then appointed as Assistant Professor of Medicine at Johns Hopkins University School of Medicine, Consultant Cardiologist, Johns Hopkins Hospital, and Director of the Experimental Cardiac Pathology Laboratory. About TFF Pharmaceuticals’ Thin Film Freezing technology platformTFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as 75% of the dose to the deep lung. Thin Film Freezing does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of Thin Film Freezing can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. About TFF PharmaceuticalsTFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com. Safe Harbor This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of any of its dry powder product candidates, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. TFF Contacts: Corporate Contact:Bill Begien VP of Investor Relations TFF Pharmaceuticals, Inc.c (617) 842-2222bbegien@tffpharma.com Investor Relations Contact:Corey Davis, Ph.D.LifeSci Advisors(212) 915-2577cdavis@lifesciadvisors.com Media Contact:Raena Mina, Ph.D.LifeSci Communicationsrmina@lifescicomms.com

Executive ChangeIPO

14 Apr 2021

·www.globenewswire.com

New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biosimilar Monoclonal Antibodies Forecast 2020-2030" - • Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound: • Infliximab • Rituximab • Abciximab • Trastuzumab • Adalimumab • Bevacizumab • This report also shows revenue to 2027 for individual biosimilar mAb products in the market: • Remsima/Inflectra • Infimab • Reditux • BI695500 • CT-P10 • BI695501 • FKB327 • FKB238 • Mabtas • AcellBia • Maball • Clotinab • Abcixirel • BCD-022 • BCD-021 • Herzuma • CANMAB/Hertraz • Our analyses show individual revenue forecasts to 2027 for these regional and national markets: • The US Biosimilar mAb Market • Japanese Biosimilar mAb Market • EU5 Biosimilar mAb Markets • BRIC and South Korea Biosimilar mAb Markets • Rest of the World Biosimilar mAb Market • This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline • Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

BiosimilarAntibody

14 Jan 2016

·renovatherapeutics.com

Renova Therapeutics appoints Dr. Richard ‘Mac’ McCloskey to head company’s clinical development efforts

Dr. McCloskey to lead clinical development An author of more than 100 peer-reviewed papers and editorials as well as three books, Dr. McCloskey has led an illustrious career in medical research and clinical practice. He has directed registration trials for Hoffman LaRoche and Centocor and was, most recently, Vice President of Scientific Affairs at Johnson & Johnson Development Corporation as well as a scientific adviser to Endo Pharmaceuticals. As Executive Vice President of Clinical Development for Renova Therapeutics, Dr. McCloskey will be responsible for all clinical aspects of the company’s trials, including preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting of clinical trial endpoints. He will also ensure Renova Therapeutics meets all regulatory requirements for clinical trial safety reporting, and, as needed, will present trial data to regulatory agencies. In this role, Dr. McCloskey will work closely with the Senior Vice President of Regulatory Affairs and Quality Assurance and will coordinate with the company’s expert consultants on statistical analysis, trial planning and conduct. His immediate focus will be on Renova Therapeutics’ lead investigational product RT-100, a single-dose gene therapy for the treatment of congestive heart failure, which recently completed a Phase 2 clinical trial. “We’re excited to have Mac join Renova as we progress further with our product pipeline,” said Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics. “His contributions in the medical field and in clinical development will be a tremendous asset to our team, as we continue to develop a portfolio of gene therapies for cardiovascular and metabolic diseases.” Dr. McCloskey received a master’s in microbiology and an M.D. from the University of Rochester and completed his medical training at Duke University and the National Institutes of Health. He has been on the faculty of the University of Texas, the University of Pennsylvania and Jefferson Medical College, and he is an emeritus fellow of the American College of Physicians and the Infectious Disease Society of America. His FDA-approved submissions include interferon, ceftriaxone, infliximab, abciximab, midazolam and injectable testosterone. He also contributed to the following as an academic clinical investigator: cefoxitin, thienamycin, cefotaxime, mezlocillin, ticarcillin, imipenem-cilastatin, cefmenoxime, amdinocillin, fleroxacin and ofloxacin. To him, taking on this role is personal: “Having been treated for congestive heart failure by the single procedure of surgical aortic valve replacement, I have both a personal and scientific appreciation of the breakthrough potential of a single treatment for CHF,” says McCloskey. “And the data derived so far for RT-100 demonstrates that potential.”

Phase 2Executive ChangeGene Therapy

100 Deals associated with Abciximab

External Link

KEGG	Wiki	ATC	Drug Bank
D02778	Abciximab	B01AC13	DB00054

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Complication	United States	Janssen Biotech, Inc.	22 Dec 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Disease	Phase 3	-	Centocor, Inc.	01 Oct 2003
Acute Ischemic Stroke	Phase 3	-	Centocor, Inc.	01 Oct 2003
Brain Ischemia	Phase 3	-	Centocor, Inc.	01 Oct 2003
Angina, Unstable	Phase 3	-	Centocor, Inc.	01 Nov 1991
Pain	Phase 2	United States	-	01 Nov 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01757457 (Pubmed \| J Cardiovasc Med (Hagerstown))	Phase 4	-	89	Intracoronary Abciximab	cerjkcjwaa(yjvinxomlx) = chvxxlndnx eodopckqvt (gmvniexqgl ) View more	-	01 Mar 2015
				Intravenous Abciximab	cerjkcjwaa(yjvinxomlx) = gkmcvyqlph eodopckqvt (gmvniexqgl ) View more
ISC2015	Not Applicable	Brain Infarction	26	Low dose IV abciximab	jtcxbjnjzc(hjvslhtcgl) = niypolloro pxekwboado (yrvuykuyub ) View more	Positive	01 Feb 2015
				Abciximab (NINDS control arms subjects)	jtcxbjnjzc(hjvslhtcgl) = nynfdwfrdp pxekwboado (yrvuykuyub ) View more
NCT00373451 (ISAR-REACT 4, Pubmed \| EuroIntervention)	Phase 4	Non-St Elevated Myocardial Infarction	1,721	Abciximab and heparin	vbnqmhobro(gmqmoczohq) = iwqarfaahh hchvxzolwg (ieptgeavpa, 0.54 - 1.34)	Positive	22 Aug 2013
				Bivalirudin	vbnqmhobro(gmqmoczohq) = tklarnwhrw hchvxzolwg (ieptgeavpa, 0.54 - 1.34)
NCT00712101 (AIDA STEMI, Pubmed \| J Am Coll Cardiol)	Phase 3	ST Elevation Myocardial Infarction	-	Intracoronary Abciximab	cyismudbbh(xiixoilpcf) = bzpcbheclb ospclokecx (aahmfbejhf, 8% - 25%)	-	02 Apr 2013
				Intravenous Abciximab	cyismudbbh(xiixoilpcf) = qdrlxxiwcs ospclokecx (aahmfbejhf, 9% - 25%)
P05.245 (AAN2013)	Not Applicable	Stroke, Lacunar	51	IV abciximab	dotxcdvydj(doidaaefxm) = lueqdefini wwpkzwgqfm (hlubawxbkn ) View more	Positive	12 Feb 2013
ISC2013	Not Applicable	Stroke	-	Low dose IV Abciximab + IV heparin	pnsqryzojl(uppqaznoai) = rjltzjmsop pxdcekauak (bqxddbbvpc ) View more	-	01 Feb 2013
				NINDS placebo subjects	pnsqryzojl(uppqaznoai) = dvevibnvgf pxdcekauak (bqxddbbvpc ) View more
NCT00986050 (DEBATER, Pubmed \| JACC Cardiovasc Interv)	Phase 4	ST Elevation Myocardial Infarction	907	abciximab (Sirolimus-eluting stents (SES))	gvxogunewn(qvlylsvgnx) = jqhdhvfqjv rbpszxcvdl (nizaideeyq ) View more	-	01 Mar 2012
				abciximab (Bare-metal stents (BMS))	gvxogunewn(qvlylsvgnx) = zulpjjjgeo rbpszxcvdl (nizaideeyq ) View more
NCT00712101 (Pubmed \| Clin Res Cardiol)	Phase 3	ST Elevation Myocardial Infarction	16	Intracoronary bolus administration of abciximab	dtvlnsjacp(timducnxwi) = hsrzxrvtfd defjaremaz (tqfgifswwt )	-	01 Feb 2012
				Intravenous bolus administration of abciximab	dtvlnsjacp(timducnxwi) = bvhywdnabj defjaremaz (tqfgifswwt )
NCT00133250 (BRAVE-3, Pubmed \| Clin Res Cardiol)	Phase 4	Acute myocardial infarction	800	Abciximab	lodsnhvtip(hvfzxvwvoh) = kimpnhjwen qtmtbepwqb (hxgcnpbeer )	Negative	01 Dec 2010
				Placebo	lodsnhvtip(hvfzxvwvoh) = rsbdsqfoom qtmtbepwqb (hxgcnpbeer )
NCT00169819 (EASY, Pubmed \| JACC Cardiovasc Interv)	Phase 4	-	-	abciximab (Same-day home discharge)	ubzltnpeiw(oesnadqfgf) = eowsbulqks ujobpwgozh (ierobyltlb )	Positive	01 Oct 2010
				abciximab (Overnight hospitalization)	ubzltnpeiw(oesnadqfgf) = ehyleqtjce ujobpwgozh (ierobyltlb )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis